NEW YORK--(BUSINESS WIRE)--The New York Times Company (NYSE: NYT) announced today that its third-quarter 2025 financial results are available on The New York Times Company's investor relations website at investors.nytco.com. As previously announced, The New York Times Company will host its earnings conference call today at 8:00 a.m. E.T. to discuss these results. A live webcast of the earnings conference call will be available at investors.nytco.com. Participants can pre-register for the teleph. ...

Core Viewpoint - Palanteer reported better than expected third quarter results and raised its full-year sales outlook, yet its shares are slightly lower despite a 150% increase in stock value this year [1]. Company Insights - Alex Karp, the CEO of Palanteer, is described as a charismatic and provocative figure who provides an unscripted view of his thoughts and motivations [2][3]. - Karp's personal background, including being biracial, Jewish, and dyslexic, has instilled a sense of vulnerability that influences his worldview and the company's mission to create a safer world [4][5]. - Palanteer's evolution includes a significant shift from primarily working with governments to also engaging with businesses, positioning itself as a potential backbone technology provider similar to IBM in the past [6][8]. Market Position - The company is often associated with surveillance, but it primarily facilitates law enforcement and intelligence operations rather than being a surveillance technology company [7]. - Palanteer has established itself as a leading provider in its field, with clients in both government and industry expressing high satisfaction with its offerings [11]. - The stock price has risen dramatically from around $10 to $200 per share over three years, indicating strong market confidence in Palanteer's future [9]. Leadership and Influence - Karp's influence on the company is profound, as Palanteer's operations reflect his personal fears and worldview [19]. - There are questions regarding Karp's long-term succession and the potential impact of his departure on the company [19][20]. - Karp has previously turned down contracts due to ethical concerns, indicating a willingness to reconsider partnerships based on moral grounds [15].

Core Insights - The New York Times Company (NYSE:NYT) is recognized as one of the few traditional newspapers that has successfully transitioned to the digital landscape, primarily generating revenue from digital subscriptions and online advertising [2][4] - The company has demonstrated significant growth in digital subscribers and revenue, with a focus on expanding its subscriber base and enhancing reader engagement [3][4] Financial Performance - In Q2 2025, NYT added approximately 230,000 net new digital-only subscribers, increasing the total to 11.88 million [4] - Average revenue per digital subscriber increased by 3.2% year-over-year to $9.64, contributing to a 15.1% year-over-year rise in digital subscription revenue [4] - Digital advertising revenue grew by 18.7%, driven by strong demand from marketers in key segments [4] Shareholder Returns - NYT has a strong track record of consistent dividend growth, raising dividends at an annual average growth rate of nearly 24% over the past five years [5] - The company has provided growing dividends for the past seven years, currently offering a quarterly dividend of $0.18 per share, resulting in a dividend yield of 1.27% as of October 30 [5]

Core Viewpoint - The Capital Link announced an investigation into LuxUrban Hotels Inc. following a misleading article by Bisnow regarding the company's bankruptcy situation, emphasizing the need for accurate reporting based on documented facts [1][8]. Summary of Misstatements vs. Documented Facts - The conversion to Chapter 7 was initiated by the U.S. Trustee and consented to by LuxUrban, contradicting claims that lenders forced the liquidation [2]. - No court order has declared an enterprise-wide shutdown of LuxUrban's operations, as the recent order merely transferred control of estate property to a Chapter 7 trustee [2]. - Allegations regarding hazardous conditions at The Herald Hotel are based on creditor pleadings and have not been adopted as judicial findings [2]. - The figure of $118.6 million owed to the New York State Department of Taxation is an asserted liability subject to objection, not an adjudicated debt [2]. - Claims of LuxUrban booking rooms while hotels were closed lack judicial findings of fraud or misconduct [2]. Chronology and Procedural Clarifications - LuxUrban filed for voluntary Chapter 11 on September 14, 2025, intending to restructure its lease portfolio and continue operations [5]. - The court approved joint administration of related affiliates on September 16, 2025, which is a routine procedure [5]. - The U.S. Trustee filed a motion on October 10, 2025, to appoint a trustee or convert to Chapter 7 [5]. - LuxUrban consented to the conversion on October 18, 2025, agreeing that liquidation was the most efficient path for stakeholders [5]. - The conversion order was entered on October 21, 2025, with no findings of misconduct or negligence [5]. - A creditors' meeting is scheduled for December 2, 2025, with approximately $123.6 million in asserted claims pending allowance or objection [5]. Procedural Integrity - LuxUrban has complied with Bankruptcy Rules and maintained counsel throughout the process, filing all required schedules [6]. Investor Litigation Reality Check - The civil case Pack v. LuxUrban Hotels Inc. is currently stayed due to bankruptcy, with no trial date or certified class existing, contrary to speculative claims about a future trial [7]. Closing Statement - The legal record presents a more nuanced narrative than the sensationalized reporting, highlighting the Debtor's consent to conversion and the absence of judicial findings of misconduct [8].

Core Viewpoint - A panel of experts concluded that claims against LuxUrban Hotels Inc. regarding large-scale tax liabilities in New York are likely inaccurate and legally precluded under state and city law, as well as inconsistent with established OTA payment systems [1][2]. Findings and Legal Basis - Between 2020 and 2025, LuxUrban Hotels generated approximately $248 million in gross room revenue across 11 U.S. states and cities, with audited net room revenue totaling $149 million, of which only $56 million (22.6%) originated from New York operations [3]. - Under New York State Tax Law, entities defined as "room remarketers" or "resellers," including OTAs, are responsible for collecting customer payments and remitting occupancy and sales taxes [4]. - Legal precedents confirm that hotels do not remit occupancy taxes for prepaid OTA transactions; instead, OTAs handle these responsibilities [5]. Implications Beyond Taxation - The OTA payment and tax structure defines the merchant-customer relationship and tax responsibility, indicating that LuxUrban did not control or process customer payments for 92–97% of its bookings [6][7]. Potential Damages and Legal Exposure of False Claims - False claims alleging unpaid taxes may expose responsible parties to defamation and commercial disparagement under New York law, with potential recoverable damages for LuxUrban reaching into the tens of millions of dollars [8][9]. - The spokesperson emphasized that the issue is a matter of law and factual record, asserting that LuxUrban neither processed guest payments nor collected occupancy taxes for OTA-booked stays [10].

Core Insights - Nongshim launched a global campaign in New York Times Square to celebrate the debut of Shin Ramyun in collaboration with Netflix's animated film 'KPop Demon Hunters' [1][4] - The campaign featured interactive activities that allowed consumers to taste Shin Ramyun, enhancing both online and offline engagement [1][4] Group 1: Campaign Details - The campaign included a giant Digital Out-of-Home (DOOH) billboard and themed booths for visitors to experience the Shin Ramyun brand [2] - Visitors sampled Shin Toomba and Shrimp Crackers, showcasing Korea's "Hangang Ramyun" culture [3] - The event featured instant photo booths and a social media follow event that offered prizes, including Shin Ramyun [3] Group 2: Global Expansion - Nongshim has been rolling out 'KPop Demon Hunters'-inspired packaging globally since late August, starting in Korea [4] - Sales in the Americas began in mid-September, with plans for expansion to key European markets and Australia/New Zealand within the year [4]

Core Insights - The Capital Link published an independent analysis titled "They Got It Wrong," examining LuxUrban Hotels Inc.'s compliance with New York State and City sales and occupancy tax requirements from 2020 to 2025 [1][4] Compliance Findings - The analysis concludes that LuxUrban's tax position aligns with New York state and city laws, indicating compliance with applicable tax regulations [2] - A significant portion of taxable transactions was processed through third-party online travel agencies (OTAs), which are responsible for collecting and remitting sales and occupancy taxes under New York law [2] Implications and Clarifications - The report aims to clarify claims of significant unpaid taxes, suggesting that public narratives may have exaggerated potential liabilities [3] - It emphasizes the importance of careful interpretation of tax filings and enforcement actions in the hospitality sector, which has broader implications for tax reporting and investor information [3]

Core Viewpoint - Major news organizations, including The New York Times, The Associated Press, and Newsmax, have decided not to sign a Defense Department document regarding its new press regulations, indicating a significant pushback against government control over media practices [1] Group 1 - The refusal to sign the document highlights concerns over press freedom and government influence on journalism [1] - The organizations involved represent a broad spectrum of the media landscape, from liberal to conservative outlets, suggesting a unified stance on the issue [1] - This decision may lead to further discussions about the role of the government in regulating media and the implications for journalistic integrity [1]

Core Insights - OS Therapies received a positive regulatory update from the European Medicines Agency (EMA) following a meeting with the Dutch Medicines Evaluation Board (MEB) on October 6, 2025, regarding its OST-HER2 Phase 2b clinical trial for osteosarcoma [2][3] Regulatory Developments - The meeting aligned on key areas such as safety, non-clinical data, and chemistry, manufacturing, and controls (CMC) data, supporting the ongoing clinical trial [3][8] - The overall survival results from the trial, showing statistically significant final two-year data, may serve as a primary endpoint for conditional marketing authorization (CMA) [3][8] - A formal EMA Scientific Advice is anticipated in December 2025, establishing a potential pathway for a confirmatory randomized clinical development program [4][10] Clinical Trial Insights - The safety profile from the Fully Resected Osteosarcoma clinical study was confirmed as positive, with data from over 500 patients treated across four other therapeutic indications potentially supporting a CMA [8] - The rapporteur indicated that overall survival (OS) could provide a stronger measure of clinical benefit compared to 12-month Event-Free Survival (EFS) [8] - Efficacy data from other settings, such as recurrent, unresectable pulmonary metastatic osteosarcoma, could be incorporated into a post-market confirmatory clinical development program [8] Market Access and Future Plans - OS Therapies has commenced the Marketing Authorisation Application (MAA) submissions process with the UK MHRA, which has granted an expedited Market Access Scientific Advice Meeting [6] - The company plans to pursue a conditional marketing authorization while advancing a global randomized clinical study to evaluate OST-HER2 in various osteosarcoma clinical settings [10] - OST-HER2 has received multiple designations from the U.S. FDA and EMA, including Rare Pediatric Disease Designation and Fast-Track status [11]

Core Insights - OS Therapies is actively participating in multiple conferences and events in October 2025, showcasing its commitment to advancing cancer treatment and engaging with industry stakeholders [1][2][3][4][5]. Company Overview - OS Therapies Inc. is a clinical-stage biotechnology company focused on developing treatments for Osteosarcoma and other solid tumors, with its lead asset being OST-HER2, an immunotherapy targeting the HER2 protein [5][6]. - OST-HER2 has received several designations from the U.S. FDA, including Rare Pediatric Disease Designation, Fast-Track, and Orphan Drug designations, indicating its potential significance in treating rare diseases [5]. - The company reported positive results from its Phase 2b clinical trial of OST-HER2, demonstrating statistically significant benefits in the 12-month event-free survival primary endpoint for patients with recurrent, fully resected, lung metastatic osteosarcoma [5]. Upcoming Events - OS Therapies will participate in the Cell and Gene Meeting on the Mesa from October 6-8, 2025, in Phoenix, AZ, focusing on partnering and one-on-one meetings [2]. - The company will also attend the Roth Annual Healthcare Opportunities Conference on October 9, 2025, in New York City, where it will engage in meetings with potential investors [2]. - A workshop on advancing osteosarcoma drug development will take place on October 10, 2025, in Washington, DC, where OS Therapies management will be available for discussions [2]. - The BIOFuture 2025 event is scheduled for October 13-15, 2025, in New York City, featuring a spotlight panel and one-on-one meetings [3]. - The company will be present at the 52nd Daytime Emmy Awards on October 17, 2025, where its documentary "Shelter Me: Cancer Pioneers" has received two nominations [3]. - The Maxim Growth Summit will occur on October 22, 2025, in New York City, where corporate presentations and meetings will be held [4]. - OS Therapies will also participate in BIO - Europe from November 3-5, 2025, in Vienna, Austria, focusing on partnering and meetings [5]. Product Development - OST-HER2 has shown preclinical efficacy in various models of breast cancer and has been conditionally approved by the U.S. Department of Agriculture for treating canines with osteosarcoma [5]. - The company is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which utilizes proprietary technology for enhanced drug delivery [6].